Merck & Co., Inc. (NEO:MRK)

Canada flag Canada · Delayed Price · Currency is CAD
22.56
+0.32 (1.44%)
At close: Dec 17, 2025
Market Cap343.94B
Revenue (ttm)89.47B
Net Income (ttm)26.51B
Shares Outn/a
EPS (ttm)10.52
PE Ratio12.97
Forward PE10.99
Dividend0.75 (3.30%)
Ex-Dividend DateDec 15, 2025
Volume11,399
Average Volume7,669
Open22.28
Previous Close22.24
Day's Range22.23 - 22.56
52-Week Range16.84 - 23.95
Beta0.30
RSI55.93
Earnings DateFeb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange Cboe Canada
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.